Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MG-K10 in Chronic Spontaneous Urticaria
NCT07546487Phase 3Not yet recruiting
- Sponsor
- Hunan Mabgeek Biotechnology
- Start
- Apr 2026
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of comekibart in chronic spontaneous urticaria (CSU), sponsored by Hunan Mabgeek Biotechnology. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
comekibart
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT07546487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07546487.